Dr Alex Troelnikov (@atroelnikov) 's Twitter Profile
Dr Alex Troelnikov

@atroelnikov

Australian Immunologist and Immunopathologist in South Australia. Climber. Amateur wood and metal worker. Father of a little human. Views are my own.

ID: 1201878358197522432

calendar_today03-12-2019 14:58:41

123 Tweet

167 Takipçi

356 Takip Edilen

Dr Alex Troelnikov (@atroelnikov) 's Twitter Profile Photo

Olink is an interesting technology and its NGS system backbone makes it an obvious choice for the UK Biobank. But the data’s value is set and defined once it’s measured. Whilst DIA MS approach would advance the field of proteomics and being it closer to being a clinical tool.

Dr Alex Troelnikov (@atroelnikov) 's Twitter Profile Photo

I predict there will be a highly effective treatment/functional cure for almost every autoimmune disease before we really understand molecularly what causes >95% of autoimmunity.

Dr Alex Troelnikov (@atroelnikov) 's Twitter Profile Photo

The Xi software suite from Rappsilber laboratory is hands down the best MS cross linking data analysis experience. Makes some others look like a steaming horse pile. Only wish is for XiView was straightforward to run locally.

Dr Alex Troelnikov (@atroelnikov) 's Twitter Profile Photo

A problem with many applications of AI in medicine is that at inception it provides a veil of sophistication, irrespective of whether the end result hinders or even could erode the practice of medicine.

Dr Alex Troelnikov (@atroelnikov) 's Twitter Profile Photo

Cool mechanism, have to think whether this could be inverted/co-opted in common immunodeficiences, like CVID. TU München cell.com/immunity/fullt…

Dr Alex Troelnikov (@atroelnikov) 's Twitter Profile Photo

Target-Decoy approaches to control FDR in mass spec seems cooked. A peptide is false if the spectra could also explain a peptide that is definitely not present in the mixture?? Does that make any actual sense?

NEJM (@nejm) 's Twitter Profile Photo

Patients with a prothrombotic clinical course often associated with thrombocytopenia may have a monoclonal paraprotein, even at low levels, that activates platelets by binding to platelet factor 4. Read the Brief Report: nej.md/4gKmrUs

Patients with a prothrombotic clinical course often associated with thrombocytopenia may have a monoclonal paraprotein, even at low levels, that activates platelets by binding to platelet factor 4. Read the Brief Report: nej.md/4gKmrUs
Dr Alex Troelnikov (@atroelnikov) 's Twitter Profile Photo

Monoclonal gammopathy of thrombotic significance with anti PF4 antibodies is the result of serendipitous mutations in a MGUS clone, mimicking the antibodies observed in VITT, with disastrous consequences. More Antibody sleuthing by Flinders immunology Flinders University nejm.org/doi/full/10.10…

Dr Alex Troelnikov (@atroelnikov) 's Twitter Profile Photo

If you are not sure how to present some data, put it into ChatGPT and have it make a plot for you. I’ve had enough pie graph abuse.

Dr Alex Troelnikov (@atroelnikov) 's Twitter Profile Photo

I really need apple M series chips to continue to scale generational performance to match the number of chrome tabs i have open

Dr Alex Troelnikov (@atroelnikov) 's Twitter Profile Photo

Choosing an open plan design for clinical/research office space only serves as a lasting example of how out of touch planners and designers are with clinicians and researchers.

Casanova Lab (@casanova_lab) 's Twitter Profile Photo

A monumental effort !!! 👇 Human inborn errors of immunity: 2024 update on the classification from the International Union of Immunological Societies Expert Committee rupress.org/jhi/article/1/…

Dr Alex Troelnikov (@atroelnikov) 's Twitter Profile Photo

Very interesting study from SAHMRI group, reminiscent of the bcg immune imprinting story. Microbial colonisation clearly symbiotic for immune responses. Wonder whether the nature of the antigens in both vaccine and bacteria is the main determinant? nature.com/articles/s4158…

Dr Alex Troelnikov (@atroelnikov) 's Twitter Profile Photo

Antibodies in immunoassays lie. If you want to measure something, just measure it, with mass spec, not with lying antibodies. Thats why it’s so disappointing that major groups are going for fancy immunoasays like O-link.

bioRxiv Immunology (@biorxiv_immuno) 's Twitter Profile Photo

Loss of B cell tolerance at the T2/T3a B cell transition is a convergent pathogenic mechanism in common variable immunodeficiency biorxiv.org/content/10.110… #biorxiv_immuno